ZP120: a nociceptin/orphanin FQ receptor ligand [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 25086585 |
| CHEMBL ID | 4297428 |
| MeSH ID | M0448783 |
| Synonym |
|---|
| ac-ryyrwkkkkkkk-nh2 |
| zp120 |
| ser-100 |
| zp-120 |
| l-lysinamide, n2-acetyl-l-arginyl-l-tyrosyl-l-tyrosyl-l-arginyl-l-tryptophyl-l-lysyl-l-lysyl-l-lysyl-l-lysyl-l-lysyl-l-lysyl- |
| 383123-18-0 |
| ser100 |
| VJ98TJ922K , |
| acetyl-arg-tyr-tyr-arg-trp-lys-lys-lys-lys-lys-lys-lys-nh2 |
| zp 120 |
| unii-vj98tj922k |
| Q27896286 |
| CHEMBL4297428 |
ZP120 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) ligand. Zealand Pharma proprietary SIP technology was used to increase the enzymatic stability and half-life of peptide.
| Excerpt | Reference | Relevance |
|---|---|---|
| "ZP120 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) ligand. " | ( Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. Calo, G; Fischetti, C; Gavioli, EC; Guerrini, R; Marzola, G; Petersen, JS; Rizzi, A; Trapella, C, 2009) | 2.01 |
| "ZP120 is a structure inducing probes modified NOP ligand: Zealand Pharma proprietary SIP technology was used to increase the enzymatic stability and half-life of peptide." | ( Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice. Calo', G; Larsen, BD; Marzola, G; Petersen, JS; Regoli, D; Rizzi, A; Rizzi, D, 2002) | 1.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " There were no serious or severe adverse events." | ( Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL-1) Partial Agonist, in Patients With Isolated Systolic Hypertension. Gulbrandsen, T; Kantola, I; Meland, N; Scheinin, M; Smerud, KT, 2017) | 0.46 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The present study examined the in vitro and in vivo pharmacodynamic profile of the novel and potentially metabolically stable NOP receptor ligand ZP120 (Ac-RYYRWKKKKKKK-NH(2)), which was created by conjugation of a structure-inducing probe (SIP) (i." | ( Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity. Kapusta, DR; Kenigs, VA; Meier, E; Petersen, JS; Quist, C; Thorkildsen, C; Vinge, MM, 2005) | 0.8 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In vivo, dose-response studies in rats showed that at doses (i." | ( Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity. Kapusta, DR; Kenigs, VA; Meier, E; Petersen, JS; Quist, C; Thorkildsen, C; Vinge, MM, 2005) | 0.6 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.73) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||